Tue, Nov 26, 2024
Volume 15, Issue 2 (Mar-Apr 2021)
mljgoums 2021, 15(2): 23-27 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
haghi B, Saghaeian jazi M, zarie M, Khosravi A, tajaldini M, Asadi J. Docetaxel Toxicity Optimization in Esophageal Squamous Cell Carcinoma Cell Line YM-1: A Study of Cell Cycle and Doubling Time Effect. mljgoums 2021; 15 (2) :23-27
URL: http://mlj.goums.ac.ir/article-1-1263-en.html
URL: http://mlj.goums.ac.ir/article-1-1263-en.html
Boshra Haghi 
1, Marie Saghaeian jazi2 , Mahdi Zarie3 , Ayyoob Khosravi3 , Mahboubeh Tajaldini4 , Jahanbakhsh Asadi5
1, Marie Saghaeian jazi2 , Mahdi Zarie3 , Ayyoob Khosravi3 , Mahboubeh Tajaldini4 , Jahanbakhsh Asadi5
1- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran , haghi.b@goums.ac.ir
2- Stem cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran
4- Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
5- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Stem cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran
4- Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
5- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (2756 Views)
Background and objectives: Docetaxel is a chemotherapeutic agent commonly used for treatment of many cancers, including esophageal squamous cell carcinoma. Docetaxel induces G2/M phase cell cycle arrest and ultimately cell death. In this study, we aimed to assess the effects of docetaxel on YM1 cells considering exposure time and dose.
Methods: After calculating the doubling time of YM1 cells, the anti-proliferative effect of different concentrations of docetaxel () [A1] after 24, 48 and 72 hours was assessed by the standard colorimetric assay. In addition, the effect of docetaxel on cell cycle was evaluated by flow cytometry.
Results: The results showed that docetaxel toxicity was not significant until 24 hours at the tested concentrations (P>0.05). In addition, the effect of docetaxel on the cells was time-dependent at all tested concentrations. Overall, the duration of exposure to docetaxel had more significant role in docetaxel toxicity in YM1 cells compared to concentration.
Conclusion: Our findings suggest that the cytotoxicity of docetaxel on YM1 cells is time-dependent.
Methods: After calculating the doubling time of YM1 cells, the anti-proliferative effect of different concentrations of docetaxel () [A1] after 24, 48 and 72 hours was assessed by the standard colorimetric assay. In addition, the effect of docetaxel on cell cycle was evaluated by flow cytometry.
Results: The results showed that docetaxel toxicity was not significant until 24 hours at the tested concentrations (P>0.05). In addition, the effect of docetaxel on the cells was time-dependent at all tested concentrations. Overall, the duration of exposure to docetaxel had more significant role in docetaxel toxicity in YM1 cells compared to concentration.
Conclusion: Our findings suggest that the cytotoxicity of docetaxel on YM1 cells is time-dependent.
[A1]Please write the concentrations
Research Article: Original Paper |
Subject:
Biochemistry
Received: 2019/11/13 | Accepted: 2019/11/13 | Published: 2021/02/28 | ePublished: 2021/02/28
Received: 2019/11/13 | Accepted: 2019/11/13 | Published: 2021/02/28 | ePublished: 2021/02/28
References
1. Song Q, Wu J-z, Wang S, Chen W-h. Elevated preoperative platelet distribution width predicts poor prognosis in Esophageal Squamous Cell Carcinoma. Scientific Reports. 2019; 9(1): 15234. [DOI:10.1038/s41598-019-51675-y] [PubMed] [Google Scholar]
2. Cui Q, Wu C, Lin D. Genomic alterations and precise medicine of esophageal squamous cell carcinoma. Journal of Bio-X Research. 2018;1(1):7-11. [View at Publisher] [DOI:10.1097/JBR.0000000000000006]
3. Gholipour M, Islami F, Roshandel G, Khoshnia M, Badakhshan A, Moradi A, et al. Esophageal Cancer in Golestan Province, Iran: A Review of Genetic Susceptibility and Environmental Risk Factors. Middle East J Dig Dis. 2016; 8(4): 249-66. [View at Publisher] [DOI:10.15171/mejdd.2016.34] [PubMed] [Google Scholar]
4. Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Annals of gastroenterological surgery. 2018; 2(4): 253-65. [DOI:10.1002/ags3.12174] [PubMed] [Google Scholar]
5. Tamaki Y, Hieda Y, Nakajima M, Kitajima K, Yoshida R, Yoshizako T, et al. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil. J Cancer. 2018; 9(16): 2765-72. [DOI:10.7150/jca.23456] [PubMed] [Google Scholar]
6. Hiramoto S, Kato K, Shoji H, Okita NT, Takashima A, Honma Y, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in patients with metastatic or recurrent esophageal squamous cell carcinoma. Journal of Clinical Oncology. 2015; 33(3_suppl): 204-. [DOI:10.1200/jco.2015.33.3_suppl.204] [PubMed] [Google Scholar]
7. Song Z, Zhang Y. Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. OncoTargets and therapy. 2014; 7: 1875-81. [DOI:10.2147/OTT.S66525] [PubMed] [Google Scholar]
8. Hurwitz MD. The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer. Transl Androl Urol. 2019;8(Suppl 3):S303-S6. [DOI:10.21037/tau.2019.06.09] [PubMed] [Google Scholar]
9. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, et al. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. Journal of Clinical Oncology. 2005;23(24):5542-51. [DOI:10.1200/JCO.2005.02.027] [PubMed] [Google Scholar]
10. Lee M-Y, Jung KS, Kim HS, Lee JY, Lim SH, Kim M, et al. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World journal of gastroenterology. 2015;21(14):4268-74. [DOI:10.3748/wjg.v21.i14.4268] [PubMed] [Google Scholar]
11. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. The oncologist. 2004;9(5):538-45. [DOI:10.1634/theoncologist.9-5-538] [PubMed] [Google Scholar]
12. Bumbaca B, Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B. 2018;8(4):518-29. [DOI:10.1016/j.apsb.2018.04.007] [PubMed] [Google Scholar]
13. Yan M, Wang J, Ren Y, Li L, He W, Zhang Y, et al. Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death & Disease. 2019;10(3):204. [DOI:10.1038/s41419-018-1248-8] [PubMed] [Google Scholar]
14. Hernández-Vargas H, Palacios J, Moreno-Bueno G. Telling Cells How to Die: Docetaxel Therapy in Cancer Cell Lines. Cell Cycle. 2007;6(7):780-3. [DOI:10.4161/cc.6.7.4050] [PubMed] [Google Scholar]
15. Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, et al. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. Journal of Experimental & Clinical Cancer Research. 2008;27(1):37. [DOI:10.1186/1756-9966-27-37] [PubMed] [Google Scholar]
16. He X, Li C, Wu X, Yang G. Docetaxel inhibits the proliferation of non-small-cell lung cancer cells via upregulation of microRNA-7 expression. International journal of clinical and experimental pathology. 2015;8(8):9072-80. [PubMed] [Google Scholar]
17. Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci. 2015;106(5):497-504. [DOI:10.1111/cas.12647] [PubMed] [Google Scholar]
18. Risinger AL, Dybdal-Hargreaves NF, Mooberry SL. Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time. Anticancer research. 2015;35(11):5845-50. [View at Publisher] [PubMed] [Google Scholar]
19. Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, et al. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015;8(3):210-6. [DOI:10.1016/j.tranon.2015.04.002] [PubMed] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.